FDA执法报告将Brandywine缓释茶碱片因第三方实验室稳定性试验中断列为II类召回
FDA drug enforcement D-0110-2027: Brandywine Pharmaceuticals, LLC — CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
openFDA药品执法报告将Brandywine Pharmaceuticals的缓释茶碱片(100 mg)召回列为II类,原因为第三方实验室稳定性试验项目中断构成CGMP偏差。召回由企业自愿发起,发起日期为2026年10月6日,报告日期为11月4日,涉批号405617(有效期2028年3月31日)共1,620瓶100片装,在全美分销,记录状态为Ongoing。
FDA drug recall enforcement report — D-0110-2027
Report issued: 2026-11-04. This is the enforcement report date, not the recall initiation date.
Scope: one classified drug product recall record; event_id may group multiple products. Unclassified records without recall numbers are outside this stream. This record is not a press release or a new enforcement finding.
The openFDA dataset is updated weekly. Report status is not a live recall status and must not be used to track the recall lifecycle. Other dates below retain their named meanings.
Complete official product record (including openFDA harmonized identifiers):
{
"address_1": "600 W Strasburg Rd",
"address_2": "",
"center_classification_date": "20261029",
"city": "West Chester",
"classification": "Class II",
"code_info": "Lot: 405617, Expiry: 03/31/2028",
"country": "United States",
"distribution_pattern": "Nationwide within U.S",
"event_id": "100038",
"initial_firm_notification": "Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",
"more_code_info": "",
"openfda": {},
"postal_code": "19382-1955",
"product_description": "Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10",
"product_quantity": "1,620 100-count bottles",
"product_type": "Drugs",
"reason_for_recall": "CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory",
"recall_initiation_date": "20261006",
"recall_number": "D-0110-2027",
"recalling_firm": "Brandywine Pharmaceuticals, LLC",
"report_date": "20261104",
"state": "PA",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov